Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Chronic Heart Failure

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 54 articles:
HTML format



Single Articles


    May 2022
  1. GUO Y, Xiao C, Zhao K, He Z, et al
    Physical Exercise Modalities for the Management of Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2022;79:698-710.
    PubMed     Abstract available


  2. CLEMENTS JN
    Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome.
    J Cardiovasc Pharmacol. 2022;79:593-604.
    PubMed     Abstract available


  3. OYESOMI ET, Tabrizchi R
    Heart and Sodium-Glucose Cotransporter 2 Inhibitors: A Sodium Dilemma.
    J Cardiovasc Pharmacol. 2022;79:641-643.
    PubMed    


  4. BILLINGSLEY H, Dixon D, Yehya A, Carbone S, et al
    Sleeve Gastrectomy Reduces BMI and Pill Count in Patients With LVAD.
    J Cardiovasc Pharmacol. 2022;79:644-645.
    PubMed    


    April 2022
  5. MARCUSOHN E, Borreda I, Hellman Y, Habib M, et al
    IV Sodium Ferric Gluconate Complex in Patients with Iron Deficiency hospitalized due to Acute Heart Failure- Investigator initiated, Randomized controlled trial.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00038.
    PubMed     Abstract available


  6. POLLESELLO P, Kivikko M
    Renal impairment in patients with acute heart failure: Are inotropes safe?
    J Cardiovasc Pharmacol. 2022 Apr 1. pii: 00005344-990000000-00016.
    PubMed    


  7. RUSSO V, Ammendola E, Gasperetti A, Bottino R, et al
    Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    J Cardiovasc Pharmacol. 2022;79:472-478.
    PubMed     Abstract available


    March 2022
  8. CUI X, Wang Z, Dong X, Cheng Z, et al
    Comparative effectiveness and safety of milrinone and levosimendan as initial inotrope therapy in acute heart failure patients with renal dysfunction.
    J Cardiovasc Pharmacol. 2022 Mar 4. pii: 00005344-990000000-00031.
    PubMed     Abstract available


    February 2022
  9. DEL BUONO MG, Damonte JI, Chiabrando JG, Markley R, et al
    Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98049.
    PubMed     Abstract available


    January 2022
  10. MCCANDLESS MG, Altara R, Booz GW, Kurdi M, et al
    What Role do Mitochondria have in Diastolic Dysfunction? Implications for Diabetic Cardiomyopathy and Heart Failure with Preserved Ejection Function (HFpEF).
    J Cardiovasc Pharmacol. 2022 Jan 21. pii: 00005344-900000000-98053.
    PubMed     Abstract available


  11. KIM Y, Byun S, Kim HY, Kim DB, et al
    Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era - systemic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98062.
    PubMed     Abstract available


  12. AL-ANI MA, Murray MR, Taha MB, Meece L, et al
    Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients.
    J Cardiovasc Pharmacol. 2022 Jan 17. pii: 00005344-900000000-98060.
    PubMed     Abstract available


    December 2021
  13. YEUNG T, Dagan M, Lankaputhra M, Cieslik L, et al
    Levosimendan and continuous outpatient support with inotropes (COSI) in patients with advanced heart failure: a single-centre descriptive study.
    J Cardiovasc Pharmacol. 2021 Dec 31. pii: 00005344-900000000-98078.
    PubMed     Abstract available


  14. CHEN PW, Trivedi A, Lee E, Dutta S, et al
    Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients with Heart Failure with Reduced Ejection Fraction.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98069.
    PubMed     Abstract available


  15. KAWADA K, Kubo T, Ishida T, Jobu K, et al
    Assisted Living and Medication Adherence in Super-Aged Patients With Heart Failure in the Japanese population.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98064.
    PubMed     Abstract available


    November 2021
  16. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    PubMed     Abstract available


  17. VIDER E, Sapir R, Mosseri E, Gavioli E, et al
    Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98119.
    PubMed     Abstract available


  18. FERNANDES C, Antonio N, Marinho V, Milner J, et al
    Digoxin in patients with advanced heart failure and sinus rhythm submitted to cardiac resynchronization therapy- is there any benefit?
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98116.
    PubMed     Abstract available


  19. AMRITPHALE A
    Right Heart Failure Management: the Achilles heel.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98115.
    PubMed    


  20. JIMENEZ-BLANCO BRAVO M, Valle A, Gayan Ordas J, Del Prado Diaz S, et al
    Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
    J Cardiovasc Pharmacol. 2021;78:e662-e668.
    PubMed     Abstract available


    October 2021
  21. MASARONE D, Melillo E, Errigo V, Martucci ML, et al
    Haemodynamic Effects of Levosimendan in Outpatients with Advanced Heart Failure: An Echocardiographic Pilot Study.
    J Cardiovasc Pharmacol. 2021 Oct 23. pii: 00005344-900000000-98126.
    PubMed     Abstract available


  22. YANG Y, Shen C, Lu J, Fu G, et al
    Sacubitril/valsartan in the treatment of right ventricular dysfunction in patients with heart failure with reduced ejection fraction: a real-world study.
    J Cardiovasc Pharmacol. 2021 Oct 21. pii: 00005344-900000000-98124.
    PubMed     Abstract available


  23. ADIE SK, Abdul-Aziz AA, Ketcham SW, Moles VM, et al
    Considerations for inotrope and vasopressor use in critically ill patients with pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98139.
    PubMed     Abstract available


    September 2021
  24. DU X, Ma Z, Li L, Zhong X, et al
    Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
    J Cardiovasc Pharmacol. 2021;78:e675-e680.
    PubMed     Abstract available


  25. DIXON DL, Billingsley HE, Canada JM, Trankle CR, et al
    Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
    J Cardiovasc Pharmacol. 2021;78:407-410.
    PubMed     Abstract available


  26. YANG M, Wang X, Wang T
    Regulation of Mitochondrial Function by Noncoding RNAs in Heart Failure and Its Application in Diagnosis and Treatment.
    J Cardiovasc Pharmacol. 2021;78:377-387.
    PubMed     Abstract available


    August 2021
  27. HUANG Y, Zhang Y, Ma L, Zhou H, et al
    Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;78:202-210.
    PubMed     Abstract available


    July 2021
  28. SHRESTHA DB, Budhathoki P, Sedhai YR, Karki P, et al
    SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
    J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98175.
    PubMed     Abstract available


  29. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
    Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
    J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
    PubMed    


    June 2021
  30. ADIE SK, Ketcham SW, Abdul-Aziz AA, Thomas MP, et al
    Characteristics of heart failure patients with or without hypotension when transitioning from nitroprusside to sacubitril-valsartan.
    J Cardiovasc Pharmacol. 2021 Jun 21. pii: 00005344-900000000-98191.
    PubMed     Abstract available


  31. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available


  32. MARUNOUCHI T, Nakashima M, Ebitani S, Umezu S, et al
    Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
    J Cardiovasc Pharmacol. 2021;77:822-829.
    PubMed     Abstract available


  33. PASCALE JV, Lucchesi PA, Garcia V
    Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.
    J Cardiovasc Pharmacol. 2021;77:707-717.
    PubMed     Abstract available


  34. YE G, Wang S, Peng D
    Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:787-795.
    PubMed     Abstract available


    May 2021
  35. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
    A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
    J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
    PubMed     Abstract available


    April 2021
  36. LONG YX, Cui DY, Kuang X, Hu S, et al
    Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98238.
    PubMed     Abstract available


    February 2021
  37. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available


    December 2020
  38. RERICK L, Elston C, Kester J, Montepara C, et al
    Evaluation of sacubitril/valsartan initiation in outpatient heart failure patients.
    J Cardiovasc Pharmacol. 2020 Dec 1. doi: 10.1097/FJC.0000000000000966.
    PubMed     Abstract available


    November 2020
  39. WOHLFORD GF, Van Tassell BW, Billingsley HE, Kadariya D, et al
    A Phase IB, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II-III Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000931.
    PubMed     Abstract available


  40. GAO D, David C, Rosa MM, Costa J, et al
    The risk of mortality associated with opioid use in patients with acute heart failure: systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000954.
    PubMed     Abstract available


  41. GIUSEPPE DEL BUONO M, Crea F, Versaci F, Biondi-Zoccai G, et al
    NLRP3 inflammasome: a new promising therapeutic target to treat heart failure.
    J Cardiovasc Pharmacol. 2020 Nov 2. doi: 10.1097/FJC.0000000000000946.
    PubMed    


    October 2020
  42. BERNIER TD, Buckley LF
    Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000929.
    PubMed     Abstract available


  43. HU J, Wu Y, Zhou X, Wang X, et al
    Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    J Cardiovasc Pharmacol. 2020;76:445-451.
    PubMed     Abstract available


    August 2020
  44. LI C, Xia W, Wang L, Zhang J, et al
    Effect of renal denervation on cardiac function and inflammatory factors in heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Aug 24. doi: 10.1097/FJC.0000000000000899.
    PubMed     Abstract available


    July 2020
  45. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available


  46. PAPP Z, Agostoni P, Alvarez J, Bettex D, et al
    Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    J Cardiovasc Pharmacol. 2020;76:4-22.
    PubMed     Abstract available


    June 2020
  47. SHEN JL, Xie XJ
    Insight into the Pro-inflammatory and Pro-Fibrotic Role of Macrophage in Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2020 Jun 4. doi: 10.1097/FJC.0000000000000858.
    PubMed     Abstract available


  48. DENG T, Wei Z, Gael A, Deng X, et al
    Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
    J Cardiovasc Pharmacol. 2020;75:535-544.
    PubMed     Abstract available


    February 2020
  49. KELLY J, Cheng J, Malloy R, Lupi K, et al
    Comparison of positive inotropic agents in the management of acute decompensated heart failure.
    J Cardiovasc Pharmacol. 2020 Feb 20. doi: 10.1097/FJC.0000000000000811.
    PubMed     Abstract available


    January 2020
  50. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available


    December 2019
  51. LTEIF C, Arwood MJ, Kansal M, Cavallari LH, et al
    Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
    J Cardiovasc Pharmacol. 2019 Dec 31. doi: 10.1097/FJC.0000000000000779.
    PubMed     Abstract available


    November 2019
  52. DEL BUONO MG, Bonaventura A, Vecchie A, Wohlford GF, et al
    Sacubitril-Valsartan for the treatment of heart failure: Time for a paragon?
    J Cardiovasc Pharmacol. 2019 Nov 29. doi: 10.1097/FJC.0000000000000782.
    PubMed    


    February 2019
  53. VICENT L, Esteban-Fernandez A, Gomez-Bueno M, De-Juan J, et al
    Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
    J Cardiovasc Pharmacol. 2019;73:118-124.
    PubMed     Abstract available


    January 2019
  54. HERPAIN A, Bouchez S, Girardis M, Guarracino F, et al
    Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.
    J Cardiovasc Pharmacol. 2019;73:3-14.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: